Arcturus Therapeutics Holdings Inc (NQ:ARCT)

9.840 -0.890 (-8.29%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

February 17, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 08, 2026

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Attend Upcoming Investor Conference

November 24, 2025

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Preview: Arcturus Therapeutics's Earnings ↗

November 07, 2025

Via Benzinga

Arcturus Therapeutics (NASDAQ:ARCT) Reports Mixed Q3 2025 Results, Extends Cash Runway to 2028 ↗

November 10, 2025

Arcturus Q3 2025 results show a revenue miss but a smaller-than-expected loss. The company advances its CF and OTC programs, with cash extending into 2028.

Via Chartmill

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

November 10, 2025

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Attend Upcoming Investor Conferences

November 04, 2025

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

October 28, 2025

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT

October 24, 2025

From Pomerantz LLP

Via GlobeNewswire

This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday ↗

October 24, 2025

Via Benzinga

Cathie Wood Goes Shopping: 3 Stocks She Just Bought ↗

October 23, 2025

The growth-focused money manager only bought three stocks on Wednesday. Let's check out that shopping list.

Via The Motley Fool

Topics ETFs

Where Arcturus Therapeutics Stands With Analysts ↗

October 22, 2025

Via Benzinga

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture ↗

October 22, 2025

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

October 22, 2025

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results ↗

October 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 22, 2025

Via Benzinga

Top movers in Wednesday's session ↗

October 22, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

October 22, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings ↗

October 22, 2025

Via Benzinga

Topics Stocks

Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off? ↗

October 22, 2025

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Via Stocktwits

Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug ↗

October 22, 2025

The company is working on a treatment for cystic fibrosis using messenger RNA, or mRNA, technology.

Via Investor's Business Daily

Wednesday's pre-market session: top gainers and losers ↗

October 22, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 22, 2025

Via Benzinga

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

October 22, 2025

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI

September 19, 2025

Via Investor Brand Network

Topics Artificial Intelligence

Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225% ↗

September 18, 2025

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),

Via Benzinga

Topics Artificial Intelligence

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.